Subscribe: Latest / All - Designed by Dr James P Howard (Google+)
ISIS-3 TRIAL |
|
|---|---|
| Problem | Suspected acute MI |
| Format | Randomised controlled trial |
| Treatment | (streptokinase OR tPA OR anistreplase) AND (aspirin + heparin OR aspirin alone) |
| Control | - |
| Population | 41299 |
| Inclusion criteria | - |
| Exclusion criteria | - |
| Follow-up | 6 months |
| Primary endpoint | 35-day mortality |
| Secondary endpoint(s) | - |
| Details | . |
| Brief summary: | UFH no benefit added to aspirin without PCI. 3 thrombolysis agents similar. |
| PAPER: ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial... | |
|---|---|
| Date | 28 Mar 1992 |
| Journal | Lancet. 1992 Mar 28;339(8796):753-70. |
| Information | Aspirin + Heparin (vs aspirin alone) -No significant medium-term survival advantage -Slightly fewer deaths during heparin treatment, but may cease when heparin stops -No significant difference with respect to total stroke -Excess of major non-cerebral bleeds -Excess of definite or probable cerebral haemorrhage Anistreplase (APSAC) vs. Streptokinase -No significant difference in re-infarction, similar 6 month survival -More allergy, slight excess strokes rtPA (vs. Streptokinase) -No significant difference in mortality -Fewer reinfarctions -Increased stroke (attributed to cerebral haemorrhage) |